DK0937100T3 - En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf - Google Patents

En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf

Info

Publication number
DK0937100T3
DK0937100T3 DK97909496T DK97909496T DK0937100T3 DK 0937100 T3 DK0937100 T3 DK 0937100T3 DK 97909496 T DK97909496 T DK 97909496T DK 97909496 T DK97909496 T DK 97909496T DK 0937100 T3 DK0937100 T3 DK 0937100T3
Authority
DK
Denmark
Prior art keywords
crystalline form
polymorphic crystalline
fluticasone propionate
new polymorphic
preparation
Prior art date
Application number
DK97909496T
Other languages
Danish (da)
English (en)
Inventor
Simon Murray Cooper
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0937100T3 publication Critical patent/DK0937100T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Disintegrating Or Milling (AREA)
  • Formation And Processing Of Food Products (AREA)
DK97909496T 1996-10-24 1997-10-23 En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf DK0937100T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9622173.4A GB9622173D0 (en) 1996-10-24 1996-10-24 Particulate Products
PCT/GB1997/002929 WO1998017676A1 (en) 1996-10-24 1997-10-23 A novel polymorphic crystalline form of fluticasone propionate, a method for its production and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
DK0937100T3 true DK0937100T3 (da) 2003-09-01

Family

ID=10801903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909496T DK0937100T3 (da) 1996-10-24 1997-10-23 En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf

Country Status (13)

Country Link
US (1) US6406718B1 (es)
EP (1) EP0937100B1 (es)
JP (1) JP2001502350A (es)
AT (1) ATE240345T1 (es)
AU (1) AU4717197A (es)
CA (1) CA2269134C (es)
DE (1) DE69722023T2 (es)
DK (1) DK0937100T3 (es)
ES (1) ES2198555T3 (es)
GB (1) GB9622173D0 (es)
PE (1) PE68099A1 (es)
PT (1) PT937100E (es)
WO (1) WO1998017676A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9828204D0 (en) * 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
ATE555773T1 (de) 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
MXPA04003321A (es) * 2001-10-10 2004-07-23 Boehringer Ingelheim Pharma Procesado de polvo con fluidos gaseosos presurizados.
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
CA2475092C (en) * 2002-02-04 2012-05-01 Baudax Bio, Inc. Nanoparticulate compositions having lysozyme as a surface stabilizer
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
CA2645080A1 (en) * 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
JP2010111592A (ja) * 2008-11-04 2010-05-20 Aska Pharmaceutical Co Ltd プロピオン酸フルチカゾンを含む局所投与剤
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
KR102163368B1 (ko) * 2011-07-08 2020-10-08 화이자 리미티드 플루티카손 프로피오네이트 형태 1의 제조 방법
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN104004044A (zh) * 2013-02-25 2014-08-27 武汉诺安药业有限公司 高纯度丙酸氟替卡松制备方法
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
ES2884849T3 (es) 2014-08-18 2021-12-13 Alkermes Pharma Ireland Ltd Composiciones de profármaco de aripiprazol
CN108066329B (zh) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 一种吸入用氟替卡松或其衍生物的微粒的制备方法
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1291A (en) * 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
JPS56138200A (en) * 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles

Also Published As

Publication number Publication date
EP0937100A1 (en) 1999-08-25
CA2269134C (en) 2007-01-09
DE69722023T2 (de) 2004-04-08
PT937100E (pt) 2003-09-30
US6406718B1 (en) 2002-06-18
EP0937100B1 (en) 2003-05-14
CA2269134A1 (en) 1998-04-30
ATE240345T1 (de) 2003-05-15
PE68099A1 (es) 1999-07-19
GB9622173D0 (en) 1996-12-18
DE69722023D1 (de) 2003-06-18
ES2198555T3 (es) 2004-02-01
JP2001502350A (ja) 2001-02-20
WO1998017676A1 (en) 1998-04-30
AU4717197A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
DK0937100T3 (da) En ny polymorfisk krystallinsk form af fluticasonpropionat, fremgangsmåder til fremstilling deraf og farmaceutiske præparater deraf
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
NO20002835D0 (no) 2-aryl-oksodihydropurinderivater, fremgangsmÕte for fremstilling av disse medisinske preparater inneholdende disse, og mellomprodukter derfor
ATE288489T1 (de) Vp-antigene des jc-virus
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
DK1024794T3 (da) Fremgangsmåde til behandling af kapsler og törre, pulveriserede farmaceutiske formuleringer
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
NO165547C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive androsta-1,4-dien-3,17-dioner.
EE04021B1 (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
NO20010277D0 (no) Benzocykloheptener, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
IS2788B (is) Búdesóníð- / formóterólefnablanda til innöndunar með lausa þéttni frá 0,30 til 0,36 g/ml, aðferð við að framleiða efnablönduna og notkun hennar
EP0907369A4 (en) MATERIALS AND METHODS FOR TREATING MULTIPLE DISEASES
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
IS1571B (is) Aðferð til framleiðslu á afleiðum tetralíns, cromans og skyldra efnasambanda til meðferðar á asma, liðagigt og skyldum sjúkdómum
IL125446A0 (en) Pharmaceutical composition for the treatment of asthma allergy and inflammation
IT9048261A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
NO983465L (no) Farmasöytisk kombinasjonspreparater inneholdende LHRH-analoger og antiöstrogener for behandling av gynekologiske forstyrrelser
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
HU9203496D0 (en) Aza-benzimidazoles applicqbles for treatment of asthma, arthritis and similqr diseases